Archives

by in
Entry Author Date Location
How A Kidney Drug Almost Torpedoed Concert Pharma’s IPO 04/25/14 Boston
Tumor Cells’ Weird Appetites for Amino Acids Are Aeglea’s Targets 02/19/14 Texas
East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More 02/14/14 Boston
Concert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share 02/13/14 Boston
East Coast Biotech Roundup: JP Morgan Edition 01/17/14 Boston
Zalicus Awaits Day of Reckoning, Braces For Key Pain Drug Results 11/11/13 Boston
East Coast Biotech Roundup: Cubist, Acetylon, Foundation, & More 08/02/13 Boston
Concert Pharma To Get $300M+ Per Drug in Celgene Pact 05/06/13 Boston
East Coast Life Sciences Roundup: Third Rock, SciFluor, Cubist 03/01/13 Boston
Concert Pharma, Jazz Pharma Strike $120M Deal for Narcolepsy 02/26/13 Boston
Page 1 of 1